Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M129Revenue $M11.2Net Margin (%)-286.2Altman Z-Score-34.0
Enterprise Value $M180EPS $-0.2Operating Margin %-183.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.9Pre-tax Margin (%)-286.2Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsY
Price/Sales11.25-y EBITDA Growth Rate %31.1Current Ratio2.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-199.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M156ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NAVBJohn Keeley 2015-06-30 Buy $1.24 - $1.67
($1.45)
$ 0.83-43%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NAVB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-12-01Sell12,500$1.5-44.67view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-11-02Sell12,500$1.98-58.08view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-10-01Sell12,500$2.27-63.44view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-09-01Sell12,500$1.88-55.85view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-08-03Sell12,500$1.71-51.46view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-06-01Sell12,500$1.24-33.06view
Troup Gordon ADirector 2015-05-29Buy10,000$1.31-36.64view
FORD BRENDAN ADirector 2015-05-21Buy20,000$1.31-36.64view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-05-01Sell12,500$1.33-37.59view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-04-01Sell20,000$1.58-47.47view

Quarterly/Annual Reports about NAVB:

    News about NAVB:

    Articles On GuruFocus.com
    Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

    More From Other Websites
    Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek® Feb 11 2016
    Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference Feb 04 2016
    Navidea Provides Update on Lymphoseek® and Immunodiagnostics Development Pipeline Feb 02 2016
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 11 2016
    Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 Million Jan 11 2016
    Navidea Appoints Anton Gueth Chairman of the Board Jan 11 2016
    Navidea Meets Guidance With 2015 Unaudited Lymphoseek® Sales of $10.2 Million Jan 11 2016
    Navidea Appoints Anton Gueth Chairman of the Board Jan 11 2016
    Navidea Biopharmaceuticals Enrolls First Patient in Pediatric Trial of Lymphoseek® Jan 06 2016
    Navidea Biopharmaceuticals Enrolls First Patient in Pediatric Trial of Lymphoseek® Jan 06 2016
    Navidea Biopharmaceuticals to Present at Biotech Showcase 2016 Jan 04 2016
    Navidea Biopharmaceuticals to Present at Biotech Showcase 2016 Jan 04 2016
    Navidea Biopharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
    Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients... Dec 10 2015
    Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients... Dec 10 2015
    NAVIDEA BIOPHARMACEUTICALS, INC. Financials Dec 08 2015
    Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput and... Dec 03 2015
    Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput and... Dec 03 2015
    Do Hedge Funds Love Navidea Biopharmaceuticals Inc (NAVB)? Nov 27 2015
    Direction of Market Influences - Research on Enova International, Navidea Biopharmaceuticals,... Nov 18 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK